Literature DB >> 22228543

Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors.

Jörgen Carlsson1.   

Abstract

High expression of epidermal growth factor receptor (EGFR)-family receptors, especially EGFR, HER2, and HER3, makes them interesting for targeted radionuclide-based imaging and therapy of disseminated cancer. The expression in some commonly occurring cancers such as breast, prostate, colorectal, and urinary bladder cancers is summarized. Possible strategies for radionuclide-based imaging and therapy are briefly discussed, especially in relation to the receptor expression in metastases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228543     DOI: 10.1007/s13277-011-0307-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  45 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 2.  Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.

Authors:  Helena R Chang
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

Review 3.  Cetuximab in the treatment of patients with colorectal cancer.

Authors:  Christopher R Garrett; Cathy Eng
Journal:  Expert Opin Biol Ther       Date:  2011-05-11       Impact factor: 4.388

4.  HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

Authors:  Nehmat Houssami; Petra Macaskill; Rosemary L Balleine; Michael Bilous; Mark D Pegram
Journal:  Breast Cancer Res Treat       Date:  2011-06-23       Impact factor: 4.872

Review 5.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 6.  New antibody conjugates in cancer therapy.

Authors:  Serengulam V Govindan; David M Goldenberg
Journal:  ScientificWorldJournal       Date:  2010-10-12

Review 7.  Trastuzumab: triumphs and tribulations.

Authors:  R Nahta; F J Esteva
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

8.  Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.

Authors:  Sun-Jin Kim; Hisanori Uehara; Takashi Karashima; David L Shepherd; Jerald J Killion; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

9.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466

10.  Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.

Authors:  E Hernes; S D Fosså; Aa Berner; B Otnes; J M Nesland
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  12 in total

1.  Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Authors:  Hanna Björkelund; Lars Gedda; Magnus Malmqvist; Karl Andersson
Journal:  Mol Clin Oncol       Date:  2012-10-30

2.  Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.

Authors:  J Carlsson; L Shen; J Xiang; J Xu; Q Wei
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

3.  CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-25

4.  Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.

Authors:  Johan Nilvebrant; Mikael Astrand; John Löfblom; Sophia Hober
Journal:  Cell Mol Life Sci       Date:  2013-06-02       Impact factor: 9.261

5.  HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides.

Authors:  Qichun Wei; Jing Xu; Li Shen; Xianhua Fu; Bicheng Zhang; Xiaofeng Zhou; Jorgen Carlsson
Journal:  Tumour Biol       Date:  2014-03-19

6.  Clinical significance of NUCB2 mRNA expression in prostate cancer.

Authors:  Hongtuan Zhang; Can Qi; Liang Li; Fei Luo; Yong Xu
Journal:  J Exp Clin Cancer Res       Date:  2013-08-16

7.  EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.

Authors:  Jörgen Carlsson; Kenneth Wester; Manuel De La Torre; Per-Uno Malmström; Truls Gårdmark
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

Review 8.  Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks.

Authors:  Timothy C Chang; Gautier Marcq; Bernhard Kiss; Dharati R Trivedi; Kathleen E Mach; Joseph C Liao
Journal:  Bladder Cancer       Date:  2017-07-27

9.  Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice.

Authors:  Meng-Zhi Zhang; Yan-Xing Guan; Jin-Xiu Zhong; Xue-Zhong Chen
Journal:  Transl Oncol       Date:  2017-05-27       Impact factor: 4.243

10.  Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.

Authors:  Joanna Strand; Hadis Honarvar; Anna Perols; Anna Orlova; Ram Kumar Selvaraju; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.